Education
Brewer received a bachelor of science from Virginia Technical in 1974 and an Master of Business Administration from Northwestern University in 1978.
Brewer received a bachelor of science from Virginia Technical in 1974 and an Master of Business Administration from Northwestern University in 1978.
At the time of his death in 2012, he was president and chief executive officer of Myrexis, which he had joined in May 2012. From 1984 to 1995, Brewer was the senior vice president of sales and marketing and later the senior vice president of Genentech Europe and Canada. Brewer was then the Chief Operating Officer of Heartport from 1996 to 1998.
In 1998, he became the president and Chief Executive Officer of Scios, a position he held until 2004.
In 2001, he was diagnosed with multiple myeloma, a form of blood cancer. In his career, Brewer guided development and commercialization of breakthrough drugs including human growth hormone for children"s growth disorders.
The first new drug in 30 years for cystic fibrosis. The first new drug in over a decade for heart failure.
Clot-busting drugs for heart attacks and strokes.
And other drugs and devices for cancer and heart disease. He served on the board of directors of several companies, including Socially Responsible Investment International. At the time of his death, he was chairman of the board of Associate of the Royal College of Art biopharma and Dendreon Corporation, and was executive chairman of Nile Therapeutics.